PPT-Modeling Imatinib-Treated Chronic Myeloid Leukemia
Author : phoebe-click | Published Date : 2017-08-25
Cara Peters cpeters3mathumdedu Advisor Dr Doron Levy dlevymathumdedu Department of Mathematics Center for Scientific Computing and Mathematical Modeling Introduction
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Modeling Imatinib-Treated Chronic Myeloi..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Modeling Imatinib-Treated Chronic Myeloid Leukemia: Transcript
Cara Peters cpeters3mathumdedu Advisor Dr Doron Levy dlevymathumdedu Department of Mathematics Center for Scientific Computing and Mathematical Modeling Introduction CML cancer of the blood. M. yeloid Leukemia. Amer Rassam, M.D.. Learning Objectives. Myeloproliferative. disorders (MPDs). Molecular . genetics of chronic myeloid . leukemia. Clinical manifestations and diagnosis of chronic myeloid leukemia. Resistance. Geoffrey L. Uy, M.D.. Associate Professor . of Medicine. Division of Oncology. Natural History of CML. Chronic Phase. Accelerated Phase. Blast Phase. Duration. 3-5 . yrs. , untreated. Varies. MPD. Myeloproliferative. . neoplasms. (MPN) constitute one of five categories of myeloid malignancies, according to the World Health Organization (WHO) classification system for hematopoietic . tumors. By: . Ashlynn. Hill. Patrice Thompson. 3 year who is battling leukemia.. The doctors suggest a bone marrow transplants for a long term survival.. Neither parents have matching bone marrows.. The parents consult with a genetic consoler and a reproductive specialist to discuss the possibilities of having another child to have matching bone marrow.. Hina. . Naushad. , M.D., Timothy C. Greiner M.D., . Radwa. El . Behery. M.D., Greg . Bociek. M.D., . Phuong L. Nguyen . M.D. . University of Nebraska Medical Center. Mayo Clinic. History. 24-year-old . Associate Professor . of Medicine. Division of Oncology. Natural History of CML. Chronic Phase. Accelerated Phase. Blast Phase. Duration. 3-5 . yrs. , untreated. Varies. Median. of months. Prognosis. 45 KEYWORDS Letterer-Siwe disease, chronic myelomonocytic leukemiaUMMARY Introduction 46 Case reportsLetterer-Siwe disease and chronic myelomyonocytic leukemiaActa Dermatoven APA Vol 19, 2010, No 1 re Amer Rassam, M.D.. Learning Objectives. Myeloproliferative. disorders (MPDs). Molecular . genetics of chronic myeloid . leukemia. Clinical manifestations and diagnosis of chronic myeloid leukemia. Overview of the treatment of chronic myeloid leukemia. Multiple Myeloma . Chronic Leukemia. Chronic leukemia consists of a number of disorders, including; . chronic myeloid leukemia. (CML) . (also called chronic . myelogenous. leukemia. Ass.Prof.Abeer. . Anwer. Ahmed. The . leukaemias. are a group of disorders characterized by . the accumulation . of malignant white cells in the bone marrow and. blood. . These . abnormal cells cause symptoms because of: . Charles G. Eberhart M.D., Ph.D.. Johns . Hopkins University. Clinical History. The patient was a 43 year-old female with a past medical history significant for . monocytic. acute myeloid leukemia (AML) with FLT3 ITD mutation. . precision . medicine at reach?. Lars . Bullinger. University of Ulm / MDC Berlin-. Buch. MODERN . PROBLEMS OF . GENETICS. dedicated . to the 115. th. anniversary of the birth of . N. W. . Timofeeff-Ressovsky. Sofia Kolovich. 1. , Allison LaRocco. 1. , . Malith. Karunasiri. 1. , Girish Rajgolikar. 1. , Allison Walker. 1. , Ramiro Garzon. 1. , Marius Bill. 1. , Adrienne Dorrance. 1. . 1. The Ohio State University Comprehensive Cancer Center, Division of Hematology, The Ohio State University, Columbus, OH 43210.. CONSULTANT HAEMATOLOGIST . HEAD OF HAEMATOLOGY DIVISION. DEPARTMENT OF PATHOLOGY. Heterogeneous group of hematopoietic . neoplasms. Uncontrolled . proliferation and . decreased apoptotic . activity with variable degrees of differentiation .
Download Document
Here is the link to download the presentation.
"Modeling Imatinib-Treated Chronic Myeloid Leukemia"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents